Skip to main content

Table 2 Demographic data, disease activity, cumulative clinical manifestations and treatments in childhood-onset systemic lupus erythematosus (cSLE) patients with autoimmune hepatitis (AIH) at diagnosis compared to those without AIH evaluated at last visit

From: Autoimmune hepatitis in 847 childhood-onset systemic lupus erythematosus population: a multicentric cohort study

Variables cSLE with AIH
(at AIH diagnosis)
(n = 7)
cSLE without AIH
(at last visit)
(n = 28)
P
Demographic data
 Age at diagnosis, years 12.25 (10.3–15.6) 12.9 (3.3–19.7) 0.650
 Disease duration, years 0 (0–8.5) 0.12 (0–8.5) 0.060
Disease activity parameter
 SLEDAI-2 K 6 (0–26) 7 (0–41) 0.755
Cumulative clinical manifestations
 Constitutional involvement 6 (86) 7 (25) 0.006
 Hepatomegaly 5 (71) 3 (11) 0.003*
 Splenomegaly 3 (43) 1 (4) 0.019
 Musculoskeletal involvement 4 (57) 3 (11) 0.018
 Serositis 0 (0) 4 (7) 1.000
 Neuropsychiatric involvement 0 (0) 5 (18) 0.559
 Renal involvement 2 (29) 11 (39) 0.689
Treatment
 Prednisone dose, mg/kg/day 1.07 (0.5–2.4) 0.9 (0.1–2.8) 0.365
 Antimalarial use 3 (43) 14 (50) 1.000
 Immunosuppressive use 6 (86) 8 (29) 0.009
  1. Results are presented in n (%) and median (range), *P - value according to Bonferroni correction for multiple comparisons (p < 0.0033), SLEDAI-2 K - SLE Disease Activity Index 2000